adamantane has been researched along with Non-alcoholic Fatty Liver Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Chang, Y; Chen, L; Cheng, Y; Han, F; Han, Z; Li, X; Lu, Y; Sun, B; Xue, M; Yang, Y | 1 |
| Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS | 1 |
| Chen, H; Chen, R; Liu, Y; Sun, J; Zhang, Z | 1 |
| Cho, MH; Jang, JE; Kim, AR; Kim, BJ; Kim, H; Kim, HJ; Kim, JH; Kim, MO; Kim, SJ; Ko, MS; Koh, EH; Lee, KU; Leem, J; Oh, JS; Park, HS; Woo, CY; Yoo, HJ | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
1 review(s) available for adamantane and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
5 other study(ies) available for adamantane and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr
Topics: Adamantane; Egypt; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Uric Acid; Vildagliptin | 2017 |
Saxagliptin regulates M1/M2 macrophage polarization via CaMKKβ/AMPK pathway to attenuate NAFLD.
Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cell Polarity; Dipeptides; Macrophages; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phosphatidylcholines; Sulfonylurea Compounds; Treatment Outcome | 2019 |
[Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes].
Topics: Adamantane; Animals; bcl-2-Associated X Protein; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Disease Models, Animal; Hepatocytes; Insulin Resistance; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley | 2014 |
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue, White; Animals; Energy Metabolism; Enzyme Inhibitors; Gene Expression Regulation; Glycolysis; Hypertrophy; Lipid Metabolism; Lipotropic Agents; Liver; Male; Mice; Mice, Mutant Strains; Mitochondrial Dynamics; Niacinamide; Non-alcoholic Fatty Liver Disease; Obesity; Oxygen Consumption | 2015 |